18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma

被引:0
|
作者
Cosimo Sperti
Claudio Pasquali
Franca Chierichetti
Andrea Ferronato
Giandomenico Decet
Sergio Pedrazzoli
机构
[1] Università di Padova,Dipartimento di Scienze Mediche e Chirurgiche, Semeiotica Chirurgica
[2] Ospedale Busonera,Department of Nuclear Medicine (F.C.)
[3] Castelfranco Veneto,undefined
来源
关键词
Fluorodeoxyglucose; positron emission tomography; standardized uptake value; pancreatic cancer; prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
The prediction of survival of patients with pancreatic cancer is usually based on tumor staging and grading and on the level of tumor markers. However, accurate tumor staging can be obtained only after resection, and still there is a great difference in survival rates among patients with the same clinicopathologic parameters. Recently the uptake of 18-fluorodeoxyglucose (FDG) by positron emission tomography (PET) has been found to be correlated with survival in patients with pancreatic cancer. This study evaluated the role of 18FDG PET as a prognostic factor for patients with pancreatic cancer. From June 1996 to July 2002, a total of 118 patients underwent PET for pancreatic cancer. The standardized uptake value (SUV) of 18FDG was calculated in 60 of them, and these patients were divided into high (>4) and low (≦4) SUV groups. They were also evaluated according to the tumor node metastasis (TNM) classification system of the International Union Against Cancer, and by tumor grade, medical or surgical treatment, diabetes, age, sex, and CA19-9 serum levels. Twenty-nine cancers showed high and 31 showed low SUVs. Survival was significantly influenced by tumor stage (P = 0.0001), tumor grade (P = 0.01), and SUV (P = 0.005). Multivariate analysis showed that only stage (P = 0.001) and SUV (P = 0.0002)were independent predictors of survival. When patients who were analyzed for SUV were stratified according to the other variables, FDG uptake was related to survival also after stratification for the following: stage III to IVa (P = 0.002), stage IVb (P = 0.01), tumor resection (P = 0.006), moderately differentiated tumors (P = 0.01), age less than 65 years (P = 0.006), CA 19–9 levels greater than 300 kU/L (P = 0.002), and absence of diabetes (P = 0.0001). The SUV calculated with 18FDG PET is an important prognostic factor for patients with pancreatic cancer and may be useful in selecting patients for therapeutic management.
引用
收藏
页码:953 / 960
页数:7
相关论文
共 50 条
  • [1] 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma
    Sperti, C
    Pasquali, C
    Chierichetti, F
    Ferronato, A
    Decet, G
    Pedrazzoli, S
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (08) : 953 - 959
  • [2] 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma - Discussion
    McHenry, L
    Pedrazzoli, S
    Prinz, R
    Howard, J
    Moser, J
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (08) : 959 - 959
  • [4] 18-Fluorodeoxyglucose positron emission tomography and pancreatic cancer
    Pedrazzoli, S
    Pasquali, C
    Sperti, C
    Chierichetti, F
    [J]. DIGESTIVE SURGERY, 2005, 22 (06) : 467 - 468
  • [5] 18-Fluorodeoxyglucose positron emission tomography and pancreatic cancer - Reply
    Ghaneh, P
    Neoptolemos, JP
    [J]. DIGESTIVE SURGERY, 2005, 22 (06) : 468 - 469
  • [6] Evaluation of 18-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic tumors
    Tanizawa, Y
    Nakagohri, T
    Konishi, M
    Inoue, K
    Oda, T
    Takahashi, S
    Nakamura, T
    Takahashi, H
    Nakahashi, C
    Murakami, K
    Ishii, H
    Nagase, M
    Kinoshita, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, : 99 - 100
  • [7] Impact of 18-Fluorodeoxyglucose Positron Emission Tomography on the Management of Pancreatic Cancer
    Izuishi, Kunihiko
    Yamamoto, Yuka
    Sano, Takanori
    Takebayashi, Ryusuke
    Masaki, Tsutomu
    Suzuki, Yasuyuki
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2010, 14 (07) : 1151 - 1158
  • [8] Impact of 18-Fluorodeoxyglucose Positron Emission Tomography on the Management of Pancreatic Cancer
    Kunihiko Izuishi
    Yuka Yamamoto
    Takanori Sano
    Ryusuke Takebayashi
    Tsutomu Masaki
    Yasuyuki Suzuki
    [J]. Journal of Gastrointestinal Surgery, 2010, 14 : 1151 - 1158
  • [9] Positron emission tomography with 18-fluorodeoxyglucose and sarcoma
    Carmoi, Thierry
    Bonardel, Gerald
    Gontier, Eric
    Algayres, Jean-Pierre
    [J]. PRESSE MEDICALE, 2010, 39 (12): : 1346 - 1347
  • [10] Usefulness of 18-fluorodeoxyglucose positron emission tomography in pediatric neurology patients
    Molloy, PT
    Alavi, A
    Vaughan, SN
    Needle, M
    Haselgrove, JC
    Mosley, PD
    Phillips, PC
    [J]. ANNALS OF NEUROLOGY, 1996, 40 (02) : 107 - 107